通过RBM15介导的代谢重编程可以促进结直肠癌的免疫反应
Chen Wang1,2,3, Mengyan Chen1,2,3, Panyu Chen1,3,4
1Department of Gastroenterology, Tongren Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Frontiers in immunology
|May 15, 2025
概括
RNA结合动机蛋白15 (RBM15) 在结直肠癌中负面调节抗瘤免疫力. 向RBM15可能会增强晚期结直肠癌患者的免疫治疗反应.
科学领域:
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
- 癌症生物学 癌症生物学
背景情况:
- 免疫检查点阻塞 (ICB) 对晚期结肠直肠癌 (CRC) 有希望,特别是在微卫星不稳定性高 (MSI-H) 瘤中.
- 然而,由于患者反应有限,需要制定改善免疫疗法疗效的策略.
研究的目的:
- 确定结直肠癌中免疫疗法反应的新型调节剂.
- 调查RNA结合基因蛋白15 (RBM15) 在结直肠癌进展和抗瘤免疫中的作用.
主要方法:
- 癌症基因组图谱 (TCGA) 结直肠癌数据集的多组分析.
- 在人类和小鼠结直肠癌细胞系中的功能性测试.
- 在同基因小鼠模型中评估瘤生长和免疫细胞透.
主要成果:
- 在结直肠癌中RBM15的表达很高,与预后不佳有关.
- 减少RBM15增加了烟酸酸酶 (FH) 的表达,降低了烟酸盐水平,增强了抗瘤免疫力.
- 抑制RBM15会延缓瘤的进展,并促进CD8+T细胞的透和激活.
结论:
- 在结直肠癌中,RBM15作为抗瘤免疫的负调节剂.
- 准RBM15是一个潜在的治疗策略,可以改善结直肠癌患者的免疫治疗结果.
相关概念视频
01:27Tumor Immunotherapy
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...